Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Corrigendum to "Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates" [Int. J. Parasitol. 48 (2018) 773-783].

Khatri V, Chauhan N, Vishnoi K, von Gegerfelt A, Gittens C, Kalyanasundaram R.

Int J Parasitol. 2018 Nov;48(13):1071. doi: 10.1016/j.ijpara.2018.09.001. Epub 2018 Oct 1. No abstract available.

2.

Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates.

Khatri V, Chauhan N, Vishnoi K, von Gegerfelt A, Gittens C, Kalyanasundaram R.

Int J Parasitol. 2018 Aug;48(9-10):773-783. doi: 10.1016/j.ijpara.2018.04.002. Epub 2018 Jun 6. Erratum in: Int J Parasitol. 2018 Nov;48(13):1071.

3.

Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.

Dakshinamoorthy G, von Gegerfelt A, Andersen H, Lewis M, Kalyanasundaram R.

PLoS One. 2014 Nov 17;9(11):e112982. doi: 10.1371/journal.pone.0112982. eCollection 2014.

4.

Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques.

Byrareddy SN, Ayash-Rashkovsky M, Kramer VG, Lee SJ, Correll M, Novembre FJ, Villinger F, Johnson WE, von Gegerfelt A, Felber BK, Ruprecht RM.

PLoS One. 2013 Sep 30;8(9):e75556. doi: 10.1371/journal.pone.0075556. eCollection 2013.

5.

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge.

Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, von Gegerfelt A, Huang W, Guan Y, Keele BF, Bess JW Jr, Piatak M Jr, Lifson JD, Williams WT, Shen X, Tomaras GD, Amara RR, Robinson HL, Johnson W, Broderick KE, Sardesai NY, Venzon DJ, Hirsch VM, Felber BK, Pavlakis GN.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2975-80. doi: 10.1073/pnas.1215393110. Epub 2013 Jan 28.

6.

IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques.

Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, Ganneru B, von Gegerfelt A, Huang W, Guan Y, Broderick KE, Sardesai NY, LaBranche C, Montefiori DC, Pavlakis GN, Felber BK.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1620-9. doi: 10.4161/hv.21407. Epub 2012 Aug 16.

7.

Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques.

Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, von Gegerfelt A, Patel V, Zhang GM, Chowdhury B, Broderick KE, Sardesai NY, Valentin A, Rosati M, Felber BK, Pavlakis GN.

Vaccine. 2011 Sep 9;29(39):6742-54. doi: 10.1016/j.vaccine.2010.12.056. Epub 2010 Dec 30.

8.

Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

von Gegerfelt A, Valentin A, Alicea C, Van Rompay KK, Marthas ML, Montefiori DC, Pavlakis GN, Felber BK.

J Immunol. 2010 Sep 15;185(6):3348-58. doi: 10.4049/jimmunol.1000572. Epub 2010 Aug 11.

9.

Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.

Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C, Jalah R, Patel V, Khan AS, Draghia-Akli R, Pavlakis GN, Felber BK.

Vaccine. 2010 Feb 23;28(8):1962-74. doi: 10.1016/j.vaccine.2009.10.099.

10.

DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.

Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C, Patel V, von Gegerfelt AS, Montefiori DC, Venzon DJ, Khan AS, Draghia-Akli R, Van Rompay KK, Felber BK, Pavlakis GN.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15831-6. doi: 10.1073/pnas.0902628106. Epub 2009 Aug 28.

11.

Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.

Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, Bergamaschi C, Alicea C, Weiss D, Treece J, Pal R, Markham PD, Marques ET, August JT, Khan A, Draghia-Akli R, Felber BK, Pavlakis GN.

Vaccine. 2008 Sep 19;26(40):5223-9. doi: 10.1016/j.vaccine.2008.03.090. Epub 2008 Apr 21.

PMID:
18468743
12.

Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.

von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK.

J Virol. 2007 Feb;81(4):1972-9. Epub 2006 Nov 29.

13.

Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques.

von Gegerfelt AS, Alicea C, Valentin A, Morrow M, van Rompay KK, Ayash-Rashkovsky M, Markham P, Else JG, Marthas ML, Pavlakis GN, Ruprecht RM, Felber BK.

AIDS Res Hum Retroviruses. 2006 Jun;22(6):516-28.

PMID:
16796527
14.

RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs.

Smulevitch S, Bear J, Alicea C, Rosati M, Jalah R, Zolotukhin AS, von Gegerfelt A, Michalowski D, Moroni C, Pavlakis GN, Felber BK.

Retrovirology. 2006 Jan 13;3:6.

15.

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Rosati M, von Gegerfelt A, Roth P, Alicea C, Valentin A, Robert-Guroff M, Venzon D, Montefiori DC, Markham P, Felber BK, Pavlakis GN.

J Virol. 2005 Jul;79(13):8480-92.

16.

Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques.

von Gegerfelt AS, Liska V, Li PL, McClure HM, Horie K, Nappi F, Montefiori DC, Pavlakis GN, Marthas ML, Ruprecht RM, Felber BK.

J Virol. 2002 Jan;76(1):96-104.

17.

Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.

Hel Z, Tsai WP, Thornton A, Nacsa J, Giuliani L, Tryniszewska E, Poudyal M, Venzon D, Wang X, Altman J, Watkins DI, Lu W, von Gegerfelt A, Felber BK, Tartaglia J, Pavlakis GN, Franchini G.

J Immunol. 2001 Dec 15;167(12):7180-91.

18.
20.

Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity.

Broliden K, Von Gegerfelt A, Persson C, Horal P, Svennerholm B, Wahren B, Björling E, Vahlne A.

AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1699-702.

PMID:
8959246
21.

Broadly reactive HIV-2 and SIVmac specific antibody-dependent cellular cytotoxicity in immunized and infected cynomolgus monkeys.

von Gegerfelt A, Nilsson C, Putkonen P, Broliden K.

Vaccine. 1994 Oct;12(13):1203-8.

PMID:
7839725
22.

Specificity of antibody-dependent cellular cytotoxicity in sera from human immunodeficiency virus type 2-infected individuals.

Von Gegerfelt A, Diaz-Pohl C, Fenyö EM, Broliden K.

AIDS Res Hum Retroviruses. 1993 Sep;9(9):883-9.

PMID:
7504937
23.

Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays.

Albert J, Björling E, von Gegerfelt A, Scarlatti G, Zhang YJ, Fenyö EM, Thorstensson R.

AIDS Res Hum Retroviruses. 1993 Jun;9(6):501-4. No abstract available.

PMID:
8394094
24.

Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.

Björling E, Scarlatti G, von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, Norrby E, Fenyö EM.

Virology. 1993 Mar;193(1):528-30.

PMID:
8438591
25.

Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals.

von Gegerfelt A, Chiodi F, Keys B, Norkrans G, Hagberg L, Fenyö EM, Broliden K.

AIDS Res Hum Retroviruses. 1992 Jun;8(6):1133-8.

PMID:
1503825
26.

Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.

Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyö EM, Wahren B, Broliden K.

Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):461-5.

27.

Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing.

Wahlberg J, Albert J, Lundeberg J, Von Gegerfelt A, Broliden K, Utter G, Fenyö EM, Uhlén M.

AIDS Res Hum Retroviruses. 1991 Dec;7(12):983-90.

PMID:
1812947
28.

Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.

Von Gegerfelt A, Albert J, Morfeldt-Månson L, Broliden K, Fenyö EM.

Virology. 1991 Nov;185(1):162-8.

PMID:
1926772
29.

Biological characterization of infectious molecular clones derived from a human immunodeficiency virus type-1 isolate with rapid/high replicative capacity.

Fredriksson R, Stålhanske P, von Gegerfelt A, Lind B, Aman P, Rassart E, Fenyö EM.

Virology. 1991 Mar;181(1):55-61.

PMID:
1704660
30.

In vitro maturation of mononuclear phagocytes and susceptibility to HIV-1 infection.

Valentin A, Von Gegerfelt A, Matsuda S, Nilsson K, Asjö B.

J Acquir Immune Defic Syndr. 1991;4(8):751-9.

PMID:
1856787
31.

Naturally occurring HIV-1 isolates with differences in replicative capacity are distinguished by in situ hybridization of infected cells.

Asjö B, Sharma UK, Morfeldt-Månson L, Magnusson A, Barkhem T, Albert J, Olausson E, Von Gegerfelt A, Lind B, Biberfeld P, et al.

AIDS Res Hum Retroviruses. 1990 Oct;6(10):1177-82.

PMID:
2252637
32.

Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.

Fenyö EM, Morfeldt-Månson L, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E, Asjö B.

J Virol. 1988 Nov;62(11):4414-9.

Supplemental Content

Loading ...
Support Center